By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nabriva Therapeutics 

Leberstrasse 20

Vienna    1112  Austria
Phone: 43-0-1-74093-0 Fax: 43-0-1-74093-1900


Company News
Nabriva Announces The Proposed Redomicile Of Its Holding Company From Austria To Ireland, By Means Of An Exchange Offer 4/17/2017 8:23:39 AM
Nabriva Announces Enrollment Completion For LEAP 1, A Phase III Clinical Trial Evaluating Lefamulin In Community-Acquired Bacterial Pneumonia 4/11/2017 10:09:36 AM
Nabriva Provides Business And Development Update And Reports 2016 Financial Results 3/27/2017 8:17:47 AM
Nabriva Confirms No Sample Size Adjustment Required For LEAP 1 Phase III Trial Of Lefamulin In Community Acquired Bacterial Pneumonia 2/2/2017 10:49:19 AM
Nabriva Announces Closing of Rights Offering and Underwritten Offering 12/20/2016 10:01:16 AM
Nabriva Achieves 60% Randomization Target In LEAP 1 Phase 3 Trial In Community Acquired Bacterial Pneumonia 12/20/2016 9:52:48 AM
Nabriva Announces Results Of Rights Offering And Pricing Of Underwritten Offering 12/15/2016 7:50:51 AM
Nabriva Announces Terms Of Rights Offering 11/30/2016 8:15:53 AM
Nabriva Announces Change In Record Date For Planned Rights Offering 11/22/2016 10:48:00 AM
Nabriva Reports Third Quarter 2016 Financial Results 11/16/2016 7:57:24 AM